HormoneInvestigational

Avexitide

A GLP-1 receptor antagonist, also known as exendin 9-39, now in Phase 3 for post-bariatric hypoglycemia.

GLP-1 AntagonistPhase 3HypoglycemiaInvestigationalExendin 9-39

Also referenced as: Exendin 9-39

Also appears in: Other

Public product evidenceSearch the public certificate ledger for this compoundNo exact compound records are currently indexed under this profile name.
Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area
Hormone signaling research

Primary research area: Hormone. Also surfaces under Other for browsing and discovery.

Aliases
1

Exendin 9-39

Signal depth
Medium

No FDA label signal · 56 trials · 529 PubMed results

Promising
Research evidence

Avexitide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Avexitide has 5 name-matched clinical trials (highest phase: Phase 3) and 529 PubMed-indexed publications and is not FDA-approved. 2 trials have posted results. Note: 2 retracted publications in the literature.

⚠ 2 retracted publications
Human data
Phase 3
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Multiple trials
Literature
High-impact
PHASE3 · RandomizedAvexitide for Treatment of Post-Bariatric HypoglycemiaPHASE2 · RandomizedAvexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic HypoglycemiaPHASE2 · RandomizedSafety and Efficacy of Exendin 9-39 in Patients With Postbariatric HypoglycemiaDiabetes · 349 citationsGlucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.The Journal of Clinical Endocrinology & Metabolism · 66 citationsPREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric HypoglycemiaDiabetes Obesity and Metabolism · 34 citationsSafety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9‐39) for treatment of post‐bariatric hypoglycaemia
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What avexitide is

Avexitide is a GLP-1 receptor antagonist better known in some research contexts as exendin 9-39.

Why it matters

Most peptide discussions focus on GLP-1 agonists that increase satiety and promote weight loss. Avexitide matters because it sits on the opposite side of that signaling story and is being developed for post-bariatric hypoglycemia.

Regulatory context

Avexitide is not FDA approved, but it has progressed into Phase 3 development.

Practical reading note

This page helps balance the library: not every clinically relevant peptide in metabolic medicine is trying to increase GLP-1 activity.